This content was current as of the date it was released. In science and medicine, information is constantly changing and may become out-of-date as new data emerge.
CLL/SLL is considered an orphan disease
The correct answer is True.
CLL may be the most common blood cancer in adults but is still quite rare and considered an orphan disease. Overall there are approximately 20,000 new cases of CLL/SLL in the United States each year. Compared to breast cancer, which has 250,000 new cases annually, and 161,000 new cases of prostate cancer, CLL/SLL is quite small.
Incidence is the term used to describe the number of new cases annually. Prevalence is the number of all patients living with the disease. With the number of new treatments that have become available for CLL/SLL in the past few years, the prevalence of CLL/SLL has been increasing as patients are living longer.
NEWS: H. R. 1409: THE CANCER DRUG PARITY ACT is pending federal legislation that helps address inequalities in how cancer treatment is paid for and deserves our support. For more information and how you can support this pending congressional bill, please see: http://peac.myeloma.org/wp-content/uploads/2013/08/HR-1409-One-Pager-March-2017.pdf
THE BASICS: Treatment Choices
In our last two issues of The CLL Bloodline, we covered what needs to be done when first diagnosed, before treatment and how to know when treatment is needed. In this issue, we broadly discuss frontline treatment choices. Treatment decision should always be individualized and depends on several factors including:
- Your age, your overall health, and any co-morbidities
- Your prognostic factors (FISH and mutation status)
- Your personal preference
Your choices are complicated and there may be significant disagreement between well- meaning experts, making it even harder to make a decision. The approved frontline treatment choices broadly fall into three categories with significant overlap: 1: Chemo-immunotherapy or CIT including FCR and BR, 2: Ibrutinib, and 3: Clinical trials. All these options are explained in much more detail in the treatment. FAQ, and clinical trial sections of our website, CLLSociety.org.
WORD/ACRONYM OF THE MONTH
Clone: A group of cells that are genetically identical and originate from a single parent cell. Leukemia cells develop from one original abnormal cell. Leukemia is an example of a clonal cancer. CLL/SLL are slow-growing blood cancers in which too many clonal white blood cells or lymphocytes are found either in the lymph nodes causing them to be enlarged, if it is SLL or in the blood and bone marrow, if it is CLL. The cells involved are identical in CLL and SLL.